StagePIPE | IPO
Natera (NASDAQ: NTRA) operates as a clinical genetic testing company. It develops and commercializes molecular testing services offering a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus as well as twin pregnancies for zygosity, a single-gene mutations screening test to identify single-gene disorder, carrier screening to determine carrier status for various genetic diseases, and more. The company was formerly known as Gene Security Network. The company was founded in 2004 and is based in Austin, Texas.
Missing: Natera's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Natera's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Natera
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Natera in 1 CB Insights research brief, most recently on Jan 20, 2021.
Expert Collections containing Natera
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Natera is included in 6 Expert Collections, including Cancer.
Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Natera has filed 178 patents.
The 3 most popular patent topics include:
- Molecular biology
Molecular biology, DNA, Genetics, Biotechnology, Molecular biology techniques
Molecular biology, DNA, Genetics, Biotechnology, Molecular biology techniques
Latest Natera News
May 26, 2023
The global minimal residual disease testing market size is expected to reach USD 4.50 billion by 2030, at a CAGR of 11.45% from 2023 to 2030. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime. MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology therapeutics. Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in Europe. Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera's diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD. Minimal Residue Disease Testing Market Report Highlights The flow cytometry segment held a dominant share in the minimal residual disease testing market in 2022 owing to the high sensitivity and wide applicability of MRD testing The hematological malignancy segment is projected to grow at the fastest rate over the forecast period owing to the increasing prevalence of hematological malignancy The hospitals and specialty clinics segment is the highest revenue-generating segment in 2022 owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics North America dominated the minimal residual disease testing market in 2022, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape Key Topics Covered: Chapter 2 Executive Summary 3.1 Minimal Residual Disease Testing Market Lineage Outlook 3.1.1 Parent Market Outlook 220.127.116.11 In Vitro Diagnostics Market Outlook 3.2 Penetration And Growth Prospect Mapping 3.3 Market Driver Analysis 3.3.2 Growing Investments In MRD Testing 3.3.3 Growing Investment For Research 3.4 Market Restraint Analysis 3.4.2 Complex Regulatory Framework Associated With MRD Testing Chapter 4 Minimal Residual Disease Testing Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million) 4.1 Definition And Scope 4.2.1 Flow Cytometry 4.2.3 Next Generation Sequencing (Ngs) 4.2.4 Others 5.1 Minimal Residual Disease Testing Market: Cancer Type Movement Analysis 5.1.1 Hematological Malignancy
Natera Frequently Asked Questions (FAQ)
When was Natera founded?
Natera was founded in 2004.
Where is Natera's headquarters?
Natera's headquarters is located at 13011 McCallen Pass Building A, Austin.
What is Natera's latest funding round?
Natera's latest funding round is PIPE.
How much did Natera raise?
Natera raised a total of $151.6M.
Who are the investors of Natera?
Investors of Natera include Roelof Botha, OrbiMed Advisors, Jennison Associates, Capital Research & Management, Sofinnova Ventures and 12 more.
Who are Natera's competitors?
Competitors of Natera include Biohope, Personal Genome Diagnostics, C2i Genomics, Sema4, Progenity, Protean BioDiagnostics, Genomic Expression, Linkage Biosciences, Sequenom, Invitae and 18 more.
Compare Natera to Competitors
JJET is committed to the development, production, and sales of products in the field of electrophysiology; the products mainly include a three-dimensional cardiac mapping system, multi-channel physiological recorder, cardiac electrophysiological stimulator, cardiac radiofrequency ablation device, cold saline perfusion pump, cardiac electrophysiological mapping catheter, cardiac radiofrequency ablation catheter, nerve radiofrequency treatment instrument. The company was founded in 1991 and is based in Chengdu, China.
Rubicor Medical is a private medical device company located in Redwood City, California. Our proprietary biopsy technology (Ovation Breast Biopsy Device) is a dramatic improvement over current minimally invasive biopsy technologies. The Ovation system is comprised of a 14-gauge biopsy device capable of excising, capturing and extracting an intact 2.5 cm diameter tissue sample. Ovation is compatible with either ultrasound or stereotactic image guidance. Rubicor was co-founded by Dr. James Vetter and has been privately funded by a consortium of individual investors. James W. Vetter, M.D., CEO and Chairman of the Board, is a board certified interventional cardiologist. He is an Associate Professor of Clinical Medicine at Stanford University Hospital, where he is currently on Active Staff status as community faculty. Dr. Vetter is a graduate of the Medical College of Wisconsin where he completed a residency in internal medicine and a fellowship in cardiology. Dr. Vetter completed an interventional cardiology fellowship with Dr. John Simpson M.D./PhD., at Sequoia Hospital, Redwood City, California. Dr. Vetter is a member of the Alpha Omega Alpha Honor Society and the American College of Cardiologists. He has published six articles and several book chapters as well as over 35 abstracts. Dr. Vetter has held positions as a member of the Physician Advisory Council and/or board member with a number of medical device companies including Guidant, Lumend, Fox Hollow and CardioVasc. He is also a board member of Magellan Systems International, Inc. Dr. Vetter has extensive experience in working with new medical device concepts and designs, working with R&D engineers to develop working prototypes and clinically testing and refining those products. He was co-founder of Perclose and was involved with that company from inception to initial public offering and eventual sale to Abbott Labs. He is a "hands on" clinician with access to resources and expertise needed to build a successful medical device and company. Dr. Vetter has had a number of patents issued in his name as co-inventor. Ary Chernomorsky, V.P. of R&D since 2000 has over 23 years experience in the medical device industry. Prior to joining Rubicor, Mr. Chernomorsky was employed by the Vascular Therapies division of US Surgical Company (acquired by Tyco International), where he served as a Director of R&D. Mr. Chernomorsky has been involved with various startup companies in the R&D Director and Manager capacities including: PAS Inc. (acquired by USS), Advanced Surgical, Inc. (acquired by Imagyn), Micro Therapeutics, Bausch and Lomb, Mentor Corporation and Dart Industries Inc. Ary holds an M.S. in Polymer Engineering from LIT and an M.S. in Biomedical Engineering from Rutgers University. Tony Difede, CPA, V.P. Finance holds a BSBA degree in Accounting from the University of Florida and a M.S. in Taxation from Pace University. He has held management positions in tax and accounting with Ernst & Young, KPMG and my CFO, Inc. His clients have included closely held start-up companies as well as large multinational public corporations. He is licensed in California and New Jersey. He has extensive experience in accounting for stock options and issues regarding closely held companies and their high net worth owners and investors. COMPANY INFO MANAGEMENT page 1 2006 Company Overview (Continued) Breast care. Completely redefined. James W. Vetter, M.D., Founder and Chairman of the Board, is a board certified interventional cardiologist. He is an Associate Professor of Clinical Medicine at Stanford University Hospital, where he is currently on Active Staff status as community faculty. Dr. Vetter is a graduate of the Medical College of Wisconsin where he completed a residency in internal medicine and a fellowship in cardiology. Dr. Vetter completed an interventional cardiology fellowship with Dr. John Simpson M.D./PhD., at Sequoia Hospital, Redwood City, Cal
Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.
StageMark is a healthcare company that intends to provide an early identification and monitoring solution for inflammatory diseases such as lupus.
MicroPhage's mission is to be a worldwide pioneer in rapid bacterial diagnostics, in both bacterial identification and antibiotic susceptibility/resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics.
Flex Biomedical is developing technologies to treat and diagnose orthopedic diseases. Flex Biomedical's lead product is a synthetic polymer, the Flex Polymer, designed to treat osteoarthritis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.